modelJ01DD15

Diagram of J01DD15

Extends from Pharmacokinetic.Models.PK_1C_enteral.

Information

name:Cefdinir
ATC code:J01DD15
route:oral
compartments:1
dosage:300mg
volume of distribution:1.03L
clearance:1.25L/h/kg
other parameters in model implementation

Cefdinir is a third-generation oral cephalosporin antibiotic used for the treatment of a variety of bacterial infections including community-acquired pneumonia, bronchitis, sinusitis, pharyngitis, and certain skin infections. It is currently approved and commonly prescribed for both adults and children.

Pharmacokinetics

Single-dose pharmacokinetic parameters in healthy adult volunteers, following oral administration.

References

  1. Guay, DR (2000). Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. The Pediatric infectious disease journal 19(12 Suppl) S141–S146. DOI:10.1097/00006454-200012001-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11144395

  2. Mao, N, et al., & Liu, X (2025). Bioequivalence of cefdinir dispersible tablets in healthy Chinese subjects under fasting and fed conditions: a single-centred, randomized, open, single-dose, two-preparation, two-cycle, two-sequence, double-crossover trial. Naunyn-Schmiedeberg's archives of pharmacology 398(6) 6821–6829. DOI:10.1007/s00210-024-03701-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39680100

  3. Pichichero, ME, et al., & Nicolau, DP (2008). Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children. Paediatric drugs 10(6) 391–397. DOI:10.2165/0148581-200810060-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18998749

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.TransferRateka (from PK_1C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_1C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)